AIRTELAFRI₦6,300.00• 0.00%
DANGCEM₦1,066.70• 0.00%
MTNN₦825.00▲ 0.61%
BUAFOODS₦760.60• 0.00%
BUACEMENT₦297.00• 0.00%
SEPLAT₦16,000.10• 0.00%
ARADEL₦1,499.90• 0.00%
FIRSTHOLDCO₦138.00• 0.00%
HBMNG₦355.00• 0.00%
ZENITHBANK₦126.00▼ 1.33%
GTCO₦124.80▼ 2.27%
TRANSCOHOT₦290.50• 0.00%
STANBIC₦160.00▼ 2.14%
PRESCO₦2,045.30• 0.00%
NB₦75.00• 0.00%
NESTLE₦2,750.00• 0.00%
GEREGU₦825.70• 0.00%
UBA₦43.00▼ 0.35%
INTBREW₦10.00▲ 0.50%
ACCESSCORP₦28.50▲ 0.71%
DANGSUGAR₦67.50▲ 0.52%
TRANSPOWER₦178.00• 0.00%
FIDELITYBK₦21.05▲ 4.73%
ETI₦71.40• 0.00%
WEMABANK₦31.00• 0.00%
OKOMUOIL₦1,276.20• 0.00%
GUINNESS₦423.00• 0.00%
FCMB₦10.80▼ 1.82%
UNILEVER₦102.50• 0.00%
UACN₦184.00• 0.00%

GDN DESKTOP 1

Advertisement

AstraZeneca to manufacture cancer killer in Singapore

By : Xinhua

Date: 20 May 2024 10:22am WAT

Follow Us on Google Discover
000_1X327D

(FILES) In this file photo taken on July 21, 2020 a general view is pictured of the offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, Cheshire. Pharmaceutical company AstraZeneca said on September 8, 2020 that it had "voluntarily paused" a randomized clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness. Paul ELLIS / AFP

(FILES) In this file photo taken on July 21, 2020 a general view is pictured of the offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, Cheshire. Pharmaceutical company AstraZeneca said on September 8, 2020 that it had "voluntarily paused" a randomized clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness. Paul ELLIS / AFP

Paul ELLIS / AFP

AstraZeneca says it will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs).

The biopharmaceutical giant announced on Monday.
[ad]
AstraZeneca aimed to start designing and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.

According to the company ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.

download guardian mobile app

Tags:

Join Our Channels

Taboola Recommendation Widget